CoChat
Sign Up
Cited by 868Hormonal and reproductive studiesAdrenal Hormones and DisordersMenopause: Health Impacts and Treatments

The DOI matches its Crossref record, with a small difference in title or year; 100 of the 102 references it cites were found in a registry or an index.

Investigation, treatment and monitoring of late-onset hypogonadism in males

Open access
Wang, C, Nieschlag, E, Swerdloff, R, Behre, H M, Hellstrom, W J, Gooren, L J, Kaufman, J M, Legros, J-J, Lunenfeld, B, Morales, A, Morley, J E, Schulman, C, Thompson, I M, Weidner, W, Wu, F C W·2008·European Journal of Endocrinology
DOI 10.1530/eje-08-0601PMC PMC2754376
Open this paper in CoChat — free accountOpen PDF

Abstract

Demographic data clearly demonstrate that the percentage of the population in the older age group is increasing. Androgen deficiency in the aging male has become a topic of increasing interest and debate throughout the world. Cross-sectional and longitudinal data indicate that the testosterone falls progressively with age and that a significant percentage of men over the age of 60 years have serum testosterone levels that are below the lower limits of young adult (age 20–30 years) men (1, 2, 3, 4). The principal questions raised by these observations are whether older hypogonadal men will benefit from testosterone treatment and what will be the risks associated with such intervention. The past decade has brought evidence of benefit of androgen treatment of hypogonadal men on multiple target organs and the recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men. This has been comprehensively reviewed and summarized by the Institute of Medicine in ‘Testosterone and Aging: Clinical Research Directions’ (5). Long-term data on the effects of testosterone treatment in the older population are limited mainly to effects on body composition and bone mass (6, 7, 8, 9, 10, 11). Key questions of the effects of testosterone on patient reported outcomes and functional benefits that may retard physical or mental frailty of the elderly or improve the quality of life are not yet available. Specific risk data on the prostate and cardiovascular systems are needed. Recent guidelines for the testosterone treatment of younger hypogonadal men are available from professional societies (12, 13, 14). Recommendations on the diagnosis, treatment, and monitoring of late-onset hypogonadism (LOH) were published by International Society for the Study of Aging Male (ISSAM) in 2002 (15). In 2005, a writing committee formed by the International Society of Andrology (ISA), the ISSAM, and the European Association of Urology (EAU) prepared a set of recommendations specifically on the ‘Investigation, treatment and monitoring of LOH’. In order to reach a large audience, these recommendations were published in the International Journal of Andrology, the Journal of Andrology, the Aging Male, and European Urology (16, 17, 18, 19). In view of the growing interest from practitioners on the treatment of older men with testosterone, the ISA, ISSAM, EAU, European Academy of Andrology, and American Society of Andrology convened meetings of the writing group with expert representatives from each of the societies. The writing group membership from 2005 was expanded to include additional urologists. Members of the writing group met in Berlin 2007, Toronto 2007, and Tampa 2008 to revise these recommendations. There was no corporate funding or support for the development of these recommendations. The revised recommendations are supported by a selection of appropriate references and categorized by the level of evidence and grade of recommendation according to the US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research (1992; Table 1). Level of evidence and grade of recommendation utilized in the recommendations. Level of evidence and grade of recommendation utilized in the recommendations. To ensure broad outreach to multidisciplinary audiences, these recommendations are published in several journals simultaneously. LOH, also referred to as age-associated testosterone-deficiency syndrome (TDS), is a clinical and biochemical syndrome associated with advancing age and characterized by symptoms and a deficiency in serum testosterone levels (below the young healthy adult male reference range) (16, 17, 18, 19, 20). This condition may result in significant detriment in the quality of life and adversely affect the function of multiple organ systems. 2.1. At present, the diagnosis of treatable hypogonadism requires the presence of symptoms and signs suggestive of testosterone deficiency (Level 3, Grade A) (12, 16, 17, 18, 19). The symptom most associated with hypogonadism is low libido (Level 3, Grade A) (21, 22). Other manifestations of hypogonadism include: erectile dysfunction, decreased muscle mass and strength, increased body fat, decreased bone mineral density and osteoporosis, and decreased vitality and depressed mood. None of these symptoms are specific to the low androgen state but may raise suspicion of testosterone deficiency. One or more of these symptoms must be corroborated with a low serum testosterone level (Level 3, Grade A) (1, 23, 24, 25). 2.2. Questionnaires such as Aging Male Symptom Score (AMS) (26, 27) and Androgen Deficiency in Aging Men (ADAM) (28) are not recommended for the diagnosis of hypogonadism because of low specificity (Level 3, Grade B) (24, 29, 30). 3.1. In patients at risk or suspected of hypogonadism, a thorough physical and biochemical work-up is necessary (Level 4, Grade A). Transient decreases of serum testostero

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1530/eje-08-0601

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 102 references

2 of the 102 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. McConnell JD Prostatic growth: new insights into hormonal regulation British Journal of Urology 76 Suppl 1 1995 5 10 7544215
  2. Nieschlag E Behre HM Testosterone: Acion, Deficiency, Substitution edn. 3. 2004 Cambridge University Press Cambridge

Cited by

Sorted by citations

Items 601–700 of 868

Related

See all

Metadata

Authors
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., Morley, J. E., Schulman, C., Thompson, I. M., Weidner, W., & Wu, F. C. W.
Affiliations
  • University of California, Los Angeles (US)
  • University of Münster (DE)
  • University Hospital in Halle (DE)
  • Tulane University (US)
  • Vrije Universiteit Amsterdam (NL)
  • Ghent University Hospital (BE)
  • University of Liège (BE)
  • Bar-Ilan University (IL)
  • St. Louis VA Medical Center (US)
  • Université Libre de Bruxelles (BE)
  • The University of Texas at San Antonio Health Science Center (US)
  • Justus-Liebig-Universität Gießen (DE)
  • Manchester Royal Infirmary (GB)
Corresponding author
Wang, C
ORCID
Venue
European Journal of Endocrinology
Publisher
Oxford University Press (OUP)
Published
2008-11
Volume
159
Issue
5
Pages
507-514
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
DOI
10.1530/eje-08-0601
PMC
PMC2754376
OpenAlex
W2097830439
Cited by
867
References
102
Citations by year
2026: 5 · 2025: 8 · 2024: 13 · 2023: 15 · 2022: 24 · 2021: 25 · 2020: 31 · 2019: 33 · 2018: 22 · 2017: 39 · 2016: 43 · 2015: 58 · 2014: 88 · 2013: 89 · 2012: 106
FWCI
60.29
Type
journal article
Language
en
Open access
Licence
Locations
  • European Journal of Endocrinology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
  • Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
andropause, male hypogonadism, testosterone replacement therapy, older men, androgen deficiency, prostate cancer risk, cardiovascular risk, treatment monitoring, quality of life, frailty, body composition, bone mass, European Association of Urology
MeSH terms
Aging, Endocrinology, Europe, Humans, Hypogonadism, Male, Age of Onset

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review